response to 2009 pandemic influenza a (h1n1) vaccine in hiv-infected patients and the influence of prior seasonal influenza vaccination应对2009年甲型流感(h1n1)疫苗感染艾滋病毒的病人和之前的季节性流感疫苗接种的影响.pdfVIP

response to 2009 pandemic influenza a (h1n1) vaccine in hiv-infected patients and the influence of prior seasonal influenza vaccination应对2009年甲型流感(h1n1)疫苗感染艾滋病毒的病人和之前的季节性流感疫苗接种的影响.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
response to 2009 pandemic influenza a (h1n1) vaccine in hiv-infected patients and the influence of prior seasonal influenza vaccination应对2009年甲型流感(h1n1)疫苗感染艾滋病毒的病人和之前的季节性流感疫苗接种的影响

Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination 1 2 3 1 1 Darius Soonawala *, Guus F. Rimmelzwaan , Luc B. S. Gelinck , Leo G. Visser , Frank P. Kroon 1 Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands, 2 Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands, 3 Department of Internal Medicine, MC Haaglanden, the Hague, The Netherlands Abstract Background: The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. ( Identifier:NC Methods and Findings: In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (FocetriaH, Novartis) was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21). Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The seroprotection rate (defined as HI titers $1:40) for HIV-infected patients was 88% after the first and 91% after the second vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%). Seroprotective titers at baseline were m

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档